SEC Approves First Cross-Asset Bitcoin-Ethereum Spot ETFs
The US Securities and Exchange Commission (SEC) has approved dual Bitcoin-Ethereum crypto index ETFs on Nasdaq from Hashdex and Franklin Templeton.
On this page
The US Securities and Exchange Commission (SEC) has approved dual Bitcoin-Ethereum crypto index ETFs on Nasdaq from Hashdex and Franklin Templeton.
These funds will allow investors to gain exposure to both cryptocurrencies within a single product.
In a December 19, 2024 press release, the regulator mentioned that after a careful review of proposed rule changes, they decided to greenlight both funds through an accelerated process.
The newly approved ETFs will be the first to integrate both Bitcoin and Ether. Previously, Bitcoin ETFs received the SEC’s approval in January, while Ethereum ETFs were approved in June 2024.
ETFs, or Exchange Traded Funds, are investment tools that you can buy and sell on stock exchanges. For example, instead of buying Bitcoin or Ethereum directly, you can invest in a crypto ETF and gain exposure to both assets.
Related: Crypto ETNs vs Crypto ETFs: Understanding the Differences
Crypto ETFs are a rising trend in the market. According to Bloomberg analysts, new crypto ETFs are expected to launch in 2025.
They predict that upcoming crypto investment products could include ETFs for Litecoin (LTC), Hedera (HBAR), Ripple (XRP), and Solana (SOL).
Currently, BlackRock’s IBIT dominates the crypto ETF market, with a total of $850 million in Bitcoin and Ethereum ETF inflows.
Other popular ETFs include Grayscale Bitcoin Trust (GBTC), Fidelity Wise Origin Bitcoin Trust (FBTC), and Bitwise Bitcoin ETF (BITB).
The content on The Coinomist is for informational purposes only and should not be interpreted as financial advice. While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, or reliability of any content. Neither we accept liability for any errors or omissions in the information provided or for any financial losses incurred as a result of relying on this information. Actions based on this content are at your own risk. Always do your own research and consult a professional. See our Terms, Privacy Policy, and Disclaimers for more details.
Articles by this author
